Browsing Tag
FDA RMAT
1 post
Base editing vs CRISPR: Why Beam Therapeutics’ sickle cell therapy may quietly become a blockbuster
Weeks after Beam’s BEAM-101 earned RMAT status, here’s why base editing may still reshape sickle cell therapy—and what investors should watch next.